Jonathan Mahler’s article in the Sept. 14 issue of The New York Times Magazine provided an excellent overview of the Trump administration’s assault on cancer research.
The Cancer Letter has published a number of excellent pieces lately on the importance of supporting and encouraging trainees and junior investigators during these uncertain times.
Ousted from her position as director of the Centers for Disease Control and Prevention less than a month after her confirmation, Susan Monarez has now had the chance to tell her side of the story before Congress.
At a two-day meeting, the Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted 8-3 to change the current recommendations that allow children under age 4 to receive the MMRV vaccine, a combination shot for measles, mumps, rubella and chickenpox (or varicella).
The American Association for Cancer Research released the results of a national survey measuring voters’ attitudes about federal funding for medical research, which found very high levels of support for federal funding for medical and cancer research across the electorate.
FDA has begun to crack down on direct-to-consumer prescription drug advertising.
A panel of doctors and lawmakers launched the bipartisan Stem Cell Therapeutic and Research Reauthorization Act of 2025 (HR 5160) and discussed its positive impacts on research, healthcare, and treatment in the United States.
Frank McCormick, of the University of California San Francisco, a pioneering scientist whose discoveries have transformed the understanding of RAS-driven cancers, was selected as recipient of the inaugural Stephenson Global Prize.
The UCSF Helen Diller Family Comprehensive Cancer Center was awarded the Specialized Programs of Research Excellence grant by NCI for a combined program focused on cancer outcomes.
The Liver Tumor Program at UT Southwestern Medical Center’s Harold C. Simmons Comprehensive Cancer Center has been selected by NCI as a Specialized Program of Research Excellence.